ReviewCommunications engineering2026
Hematologic complications and design challenges in cardiovascular devices.
Review in Communications engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we provide an engineering assessment of prevalent blood-wetted cardiovascular devices, their hematologic complications, and their interconnections to identify key areas for future research. In fact, the incidence of cardiovascular diseases has promoted the development of various devices to treat these conditions, including mechanical circulatory supports (mechanical pumps that assist or replace failing hearts), artificial valves to replace faulty heart valves, stents to relieve obstructions in blood vessels, vascular grafts to repair/reconstruct damaged vessels, patches to reinforce or reconstruct cardiovascular tissues, and other implants. The hemocompatibility of these cardiovascular devices, namely their ability to interact with blood flow without causing adverse reactions, remains unsatisfactory, and recurrent complications include thrombosis, hemolysis, and bleeding. Therefore, the discussion provided herein will support readers approaching cardiovascular technologies in building a solid foundation and provide everyone with an up-to-date overview of ongoing research in this multidisciplinary field.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.